Pages that link to "Q33383727"
Jump to navigation
Jump to search
The following pages link to Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 (Q33383727):
Displaying 50 items.
- A new standard of care for the management of peritoneal surface malignancy (Q24626790) (← links)
- Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells (Q26751018) (← links)
- A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer (Q26775711) (← links)
- A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer (Q26782245) (← links)
- Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? (Q26859632) (← links)
- Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer (Q30422446) (← links)
- Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program (Q30972278) (← links)
- Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620 (Q31115121) (← links)
- Post-marketing Surveillance (PMS) of all Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13 935 Patients (Q33396774) (← links)
- Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey (Q33406703) (← links)
- Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer (Q33414068) (← links)
- Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. (Q33558979) (← links)
- Comparison of error rates in single-arm versus randomized phase II cancer clinical trials (Q33813448) (← links)
- CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH (Q33819683) (← links)
- Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal (Q33906344) (← links)
- Isolated hepatic perfusion for patients with liver metastases (Q33937362) (← links)
- Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer (Q33983663) (← links)
- Surgery of the primary in stage IV colorectal cancer with unresectable metastases (Q34029799) (← links)
- Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics (Q34048515) (← links)
- NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. (Q34050521) (← links)
- Circulating tumor cells in colorectal cancer: past, present, and future challenges (Q34097734) (← links)
- A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI (Q34108206) (← links)
- Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway (Q34150655) (← links)
- A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial (Q34206726) (← links)
- Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? (Q34207776) (← links)
- Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy (Q34349053) (← links)
- Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases (Q34360237) (← links)
- Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction (Q34366871) (← links)
- Prognostic and predictive response factors in colorectal cancer patients: between hope and reality (Q34467133) (← links)
- Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. (Q34529351) (← links)
- FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping (Q34583743) (← links)
- Fool's gold, lost treasures, and the randomized clinical trial (Q34669260) (← links)
- Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials (Q34716556) (← links)
- Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community (Q34734413) (← links)
- The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. (Q35055207) (← links)
- Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. (Q35076251) (← links)
- Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. (Q35332617) (← links)
- Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study (Q35584825) (← links)
- Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases (Q36063355) (← links)
- Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes (Q36083102) (← links)
- A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study (Q36105171) (← links)
- Meta-analysis of outcomes of patients with stage IV colorectal cancer managed with chemotherapy/radiochemotherapy with and without primary tumor resection (Q36206186) (← links)
- A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. (Q36211254) (← links)
- Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). (Q36278103) (← links)
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study (Q36862851) (← links)
- Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study (Q36869744) (← links)
- Liver resection for colorectal cancer metastases (Q36897808) (← links)
- Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum (Q36963757) (← links)
- Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy (Q36967977) (← links)
- A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion (Q36977424) (← links)